After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The health care sector is booming, but many stocks are overvalued. We pinpoint the best buys now in the medical device niche.
These medical device makers could be acquisition targets (and one buyer) following Zimmer Biomet's takeout of LDR Holding. Their charts are also buys, says technical chartist Bruce Kamich.
The $1 billion transaction could inspire other medical device companies and private equity firms to bend over backwards for spinal device assets.
The hefty premium Zimmer Biomet is paying in the $1 billion deal for the spine company suggests the target's management followed a competitive process.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.